Prognostic Markers in Meningioma: Effectiveness of FISH‐Assessed CDKN2A/B Homozygous Deletion and Limits of Surrogate p16/MTAP Immunohistochemistry in Predicting Disease‐Specific Survival
Neuropathology and Applied Neurobiology · 2026
DOI: 10.1111/nan.70101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropathology and Applied Neurobiology, 2026. Verfasst von Alessia Andrea Ricci und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Unit, Department of Medical Sciences, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase Inhibitor p16, Meningioma, Meningeal Neoplasms, Cyclin-Dependent Kinase Inhibitor p15. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Ricerca Molinette ETS, Rete Oncologica Piemonte e Valle d'Aosta, Fondazione CRT.
Abstract (Originalsprache)
Aims
Homozygous deletion (HD) of CDKN2A/B represents an adverse prognostic biomarker in meningiomas and a diagnostic criterion for CNS WHO grade 3 assignment. However, fluorescence in situ hybridisation (FISH) thresholds and the role of immunohistochemistry (IHC) surrogates remain uncertain. This study evaluated multiple CDKN2A/B FISH cutoffs and assessed the diagnostic and prognostic performance of MTAP and p16 IHC. Methods and Results Ninety‐two meningiomas (CNS WHO grades 1–3) were analysed by FISH evaluating ≥ 10%, ≥ 20% and ≥ 30% CDKN2A/B HD thresholds. CDKN2A/B HD was identified in 18.5%, 6.5% and 4.3% of cases using the respective cutoffs and was significantly associated with shorter disease‐specific survival across all thresholds (HD ≥ 10% p = 0.001 ; HD ≥ 20% p = 0.0001; HD ≥ 30% p = 0.043). Patients with HD ≥ 20% and ≥ 30% experienced universal disease‐specific mortality within a median survival time of approximately 2 years. MTAP and p16 IHC were performed in matched areas. MTAP IHC showed high specificity (90%–92%) but limited sensitivity (30%–50%), while p16 IHC displayed variable sensitivity (41%–75%) and lower specificity (63%). Combined MTAP/p16 negativity improved sensitivity (up to 100%) but reduced specificity (57%). Neither MTAP nor p16 loss correlated significantly with survival. Spatially heterogeneous IHC patterns corresponded to regional variability in CDKN2A/B deletion by FISH.
Conclusions
CDKN2A/B HD detected by FISH, particularly using thresholds equal or greater than 20%, is strongly associated with poor outcome in meningiomas. MTAP and p16 IHC, alone or combined, lack sufficient accuracy as independent surrogates but may guide tissue selection for molecular testing in heterogeneous tumours.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pathology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
- Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy.
- Pathology Unit, Department of Laboratory Medicine, "Città della Salute e della Scienza" University Hospital, Turin, Italy.
- Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
- Neurosurgery Unit, "Città della Salute e della Scienza" University Hospital, University of Turin, Turin, Italy.
- Department of Oncology, University of Turin, Turin, Italy.
ORCID-Profile: Alessia Andrea Ricci, Filippo Nozzoli, Roberta Rudà, Camilla Bonaudo, Isacco Desideri, Paola Cassoni, Luca Bertero
Förderung
- Fondazione Ricerca Molinette ETS
- Rete Oncologica Piemonte e Valle d'Aosta
- Fondazione CRT
Zitieren
APA
Ricci, A. A., Nozzoli, F., Biale, A., Tampieri, C., Verdun di Cantogno, L., Garbossa, D., Levis, M., Rudà, R., Bonaudo, C., Della Puppa, A., Livi, L., Desideri, I., Cassoni, P., & Bertero, L. (2026). Prognostic Markers in Meningioma: Effectiveness of FISH‐Assessed CDKN2A/B Homozygous Deletion and Limits of Surrogate p16/MTAP Immunohistochemistry in Predicting Disease‐Specific Survival. Neuropathology and Applied Neurobiology. https://doi.org/10.1111/nan.70101
Vancouver
Ricci AA, Nozzoli F, Biale A, Tampieri C, Verdun di Cantogno L, Garbossa D, et al. Prognostic Markers in Meningioma: Effectiveness of FISH‐Assessed CDKN2A/B Homozygous Deletion and Limits of Surrogate p16/MTAP Immunohistochemistry in Predicting Disease‐Specific Survival. Neuropathology and Applied Neurobiology. 2026. doi:10.1111/nan.70101
BibTeX
@article{Ricci2026,
author = {Ricci, Alessia Andrea and Nozzoli, Filippo and Biale, Alessandro and Tampieri, Cristian and Verdun di Cantogno, Ludovica and Garbossa, Diego and Levis, Mario and Rudà, Roberta and Bonaudo, Camilla and Della Puppa, Alessandro and Livi, Lorenzo and Desideri, Isacco and Cassoni, Paola and Bertero, Luca},
title = {Prognostic Markers in Meningioma: Effectiveness of FISH‐Assessed CDKN2A/B Homozygous Deletion and Limits of Surrogate p16/MTAP Immunohistochemistry in Predicting Disease‐Specific Survival},
journal = {Neuropathology and Applied Neurobiology},
year = {2026},
doi = {10.1111/nan.70101}
}
EUVIMED